Cytek Biosciences (NASDAQ:CTKB - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.05), Zacks reports. Cytek Biosciences had a negative return on equity of 2.58% and a negative net margin of 5.05%. Cytek Biosciences updated its FY 2025 guidance to EPS.
Cytek Biosciences Stock Performance
Shares of CTKB stock traded down $0.87 on Friday, hitting $2.92. 2,223,253 shares of the company's stock traded hands, compared to its average volume of 717,075. The stock has a market capitalization of $372.59 million, a price-to-earnings ratio of -36.50 and a beta of 1.42. The company's fifty day simple moving average is $3.90 and its 200 day simple moving average is $5.25. Cytek Biosciences has a one year low of $2.87 and a one year high of $7.63.
Analysts Set New Price Targets
A number of equities analysts have commented on CTKB shares. TD Cowen cut shares of Cytek Biosciences from a "buy" rating to a "hold" rating and set a $4.00 price target for the company. in a research note on Friday. The Goldman Sachs Group set a $5.25 target price on shares of Cytek Biosciences in a research report on Sunday, February 2nd. Piper Sandler lowered their price target on Cytek Biosciences from $8.50 to $8.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 4th. Finally, Stephens reiterated an "overweight" rating and issued a $6.00 price objective on shares of Cytek Biosciences in a report on Wednesday, March 19th.
View Our Latest Stock Analysis on CTKB
Cytek Biosciences Company Profile
(
Get Free Report)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cytek Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytek Biosciences wasn't on the list.
While Cytek Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
